Which are best candidates from existing drug molecules for use as antiviral drug against Novel Corona Virus 19.
1) Existing drugs which hold molecular similarities and properties which can potentially exhibit antiviral activity in treatment of novel corona virus 19 are listed below.
Diethylcarbamazine (DEC) once was studied for enhancing the antibody generation in patients infected with HIV, and it is found that it has good antiviral activity as well.
Its molecular structure is makes it potential competitive inhibitor for pyrimidine bases during transcription. Also a negative feedback mechanism can increase the antibody well before the virus becomes harmful to the lungs tissue.
a dose of 10 mg / per kg/ day will be useful in treatment of Novel Corona Virus19 and management of covid19.
Abstract from An available study conducted by Kitchen Lynn W. M.d, Harvard University and later which was patented is provided below.
1) Protease inhibitors Drugs that inhibit nucleotide by presenting themselves as competitive inhibitor of RNA elongation and protein synthesis by inhibiting Uracil, Cytocin, and Adenine neucliotides, in order to achieve this drugs those resemble in the structure orientation to Uracil, Cytocin, and Adenine nucleotide to be chosen
Following drugs are already in existence and approved as antiviral drugs, and hold many structural similar portions in their molecule which has capability to present that portion to polymerase enzyme and bind bases in the RNA and DNA during the process of translation and protein synthesis.
One Combinition
1) Lopinavir.(LPV)
2) Ritonavir. (RTV)
3) Saquinavir (SQV) or Cidofovir
+
2) Diethylcarbamazine (DEC)
These drugs to be taken in combination all together as
One dose L/R and another of C will ensure that the viral RNA synthesis is provided competitive drug molecules for competitive inhibition of RNA elongation.
Following is the detail chart with structural similarity identification for selection of drug candidate is done for Protease inhibitor category of drugs.
1) Protease inhibitors in existing class of drugs used in the treatment of HIV infection.
1) Lopinavir.(LPV)
2) Ritonavir. (RTV)
3) Cidofovir (C)
First dose in morning Combination of 1) Lopinavir.(LPV) + 2) Ritonavir (RTV) Combination with 3) Saquinavir (SQV) or 3) Cidofovir
+ Diethylcarbamazine (DEC) 10 mg/kg body weight.
Referance: https://patents.google.com/patent/US4900548A/en
Kitchen Lynn W. M.d, Harvard University
1) Existing drugs which hold molecular similarities and properties which can potentially exhibit antiviral activity in treatment of novel corona virus 19 are listed below.
2) Diethylcarbamazine (DEC): Diethylcarbamazine(DEC) as Antiviral or in the therapy of novel corona Virus.
Diethylcarbamazine (DEC) once was studied for enhancing the antibody generation in patients infected with HIV, and it is found that it has good antiviral activity as well.
Its molecular structure is makes it potential competitive inhibitor for pyrimidine bases during transcription. Also a negative feedback mechanism can increase the antibody well before the virus becomes harmful to the lungs tissue.
a dose of 10 mg / per kg/ day will be useful in treatment of Novel Corona Virus19 and management of covid19.
 |
| Diethylcarbamazine |
Abstract from An available study conducted by Kitchen Lynn W. M.d, Harvard University and later which was patented is provided below.
1) Protease inhibitors Drugs that inhibit nucleotide by presenting themselves as competitive inhibitor of RNA elongation and protein synthesis by inhibiting Uracil, Cytocin, and Adenine neucliotides, in order to achieve this drugs those resemble in the structure orientation to Uracil, Cytocin, and Adenine nucleotide to be chosen
Following drugs are already in existence and approved as antiviral drugs, and hold many structural similar portions in their molecule which has capability to present that portion to polymerase enzyme and bind bases in the RNA and DNA during the process of translation and protein synthesis.
One Combinition
1) Lopinavir.(LPV)
2) Ritonavir. (RTV)
3) Saquinavir (SQV) or Cidofovir
+
2) Diethylcarbamazine (DEC)
These drugs to be taken in combination all together as
One dose L/R and another of C will ensure that the viral RNA synthesis is provided competitive drug molecules for competitive inhibition of RNA elongation.
Following is the detail chart with structural similarity identification for selection of drug candidate is done for Protease inhibitor category of drugs.
1) Protease inhibitors in existing class of drugs used in the treatment of HIV infection.
1) Lopinavir.(LPV)
2) Ritonavir. (RTV)
3) Cidofovir (C)
First dose in morning Combination of 1) Lopinavir.(LPV) + 2) Ritonavir (RTV) Combination with 3) Saquinavir (SQV) or 3) Cidofovir
+ Diethylcarbamazine (DEC) 10 mg/kg body weight.
Referance: https://patents.google.com/patent/US4900548A/en
Kitchen Lynn W. M.d, Harvard University
No comments:
Post a Comment